CDK9 and neoplasm: In this context, inhibitors targeting the transcription-associated CDKs (including CDK7, CDK8, CDK9, CDK12, and CDK13) have gained attention as attractive candidates to suppress tumor-specific signaling cascades [31,32,33,34,35].